Duration of androgen deprivation with radio-therapy for high-risk or locally advanced prostate cancer: A network meta-analysis.
Fausto PetrelliAgostina De StefaniIvano VavassoriFederica MottaAndrea LucianiFrancesca TrevisanPublished in: Tumori (2023)
We found that 36 months of adjuvant androgen deprivation therapy after radiotherapy was the optimal duration of endocrine treatment with regard to cancer mortality for high-risk and locally advanced prostate cancer.
Keyphrases
- locally advanced
- prostate cancer
- rectal cancer
- neoadjuvant chemotherapy
- squamous cell carcinoma
- radical prostatectomy
- radiation therapy
- phase ii study
- early stage
- papillary thyroid
- cardiovascular events
- squamous cell
- lymph node metastasis
- cardiovascular disease
- clinical trial
- young adults
- cell therapy
- childhood cancer
- replacement therapy
- open label